Grifols (NASDAQ:GRFS) ADRs hit a 52-week high on Friday after the Spanish plasma therapeutics company announced an agreement to sell ~20% of its equity stake in Shanghai RAAS to Haier Group for ...

The takeover deliberations come shortly after Grifols completed the sale of its 20% stake in Chinese blood products unit Shanghai RAAS to Haier, a deal first announced in 2020, raising cash of ...

Grifols (GRFS) has established a partnership with the Biomedical Advanced Research and Development Authority to test investigational ocular surface immunoglobulin eye drops for their ability to ...